| A |
| admin-023 |
Administrative Denials
|
September 01, 2021 |
May 26, 2021 |
May 26, 2022 |
| D |
| mp-026 |
Drug Levels and Antibody Testing for Infliximab, Adalimumab, Vedolizumab and Ustekinumab
|
September 20, 2021 |
July 15, 2021 |
July 15, 2022 |
| reimb-030 |
Durable Medical Equipment (DME)
|
October 06, 2021 |
August 06, 2021 |
August 06, 2022 |
| H |
| reimb-010 |
Home Health Aide Services
|
May 23, 2022 |
March 23, 2022 |
March 23, 2023 |
| admin-016 |
Hospice Eligibility Determination Policy
|
March 26, 2022 |
January 26, 2022 |
January 26, 2023 |
| M |
| reimb-034 |
Multiple Procedure Payment Reduction (MPPR)
|
September 01, 2021 |
July 01, 2021 |
July 01, 2022 |
| N |
| reimb-007 |
Next Generation Sequencing (NGS) Genetic Testing
|
October 06, 2021 |
August 6, 2021 |
August 06, 2022 |
| P |
| reimb-026 |
Prolonged Services
|
September 01, 2021 |
May 19, 2021 |
May 19, 2022 |
| R |
| admin-022 |
Retrospective Service Reviews
|
September 01, 2021 |
May 26, 2021 |
May 26, 2022 |
| S |
| MP-069 |
Serologic Testing for Liver Fibrosis
|
April 23, 2022 |
February 23, 2022 |
February 23, 2023 |
